Elutia to Participate in Chardan’s Trending Issues in Drug Development Conference Series on April 29
Elutia (Nasdaq: ELUT), a leader in drug-eluting biomatrix technologies, has announced its participation in Chardan's Trending Issues in Drug Development Conference Series. The company's Chief Scientific Officer, Dr. Michelle LeRoux Williams, will join a fireside chat discussion focused on 'Data & Regulatory Catalysts – Navigating an Evolving Landscape' on Tuesday, April 29, 2025, at 11:00 a.m. ET.
The virtual event will be accessible to investors and interested parties through a live webcast, with an archived version available afterward on the company's investor relations website at investors.elutia.com.
Elutia (Nasdaq: ELUT), leader nelle tecnologie di biomatrice a rilascio di farmaci, ha annunciato la sua partecipazione alla serie di conferenze Chardan sui temi attuali nello sviluppo farmaceutico. La Chief Scientific Officer dell'azienda, la Dott.ssa Michelle LeRoux Williams, prenderà parte a una discussione informale incentrata su 'Dati e catalizzatori normativi – Navigare in un panorama in evoluzione' martedì 29 aprile 2025 alle 11:00 ET.
L'evento virtuale sarà accessibile agli investitori e agli interessati tramite una diretta webcast, con una versione registrata disponibile successivamente sul sito web delle relazioni con gli investitori dell'azienda all'indirizzo investors.elutia.com.
Elutia (Nasdaq: ELUT), líder en tecnologías de biomatrices liberadoras de fármacos, ha anunciado su participación en la serie de conferencias sobre temas actuales en desarrollo farmacéutico de Chardan. La directora científica de la empresa, la Dra. Michelle LeRoux Williams, participará en una charla informal centrada en 'Datos y catalizadores regulatorios – Navegando un panorama en evolución' el martes 29 de abril de 2025 a las 11:00 a.m. ET.
El evento virtual estará disponible para inversores y personas interesadas a través de una transmisión en vivo, con una versión archivada que podrá consultarse posteriormente en la página web de relaciones con inversores de la empresa en investors.elutia.com.
엘루티아 (나스닥: ELUT)는 약물 방출 바이오매트릭스 기술 분야의 선두주자로서, 차던의 신약 개발 최신 이슈 컨퍼런스 시리즈에 참여한다고 발표했습니다. 회사의 최고 과학 책임자인 미셸 르루 윌리엄스 박사는 2025년 4월 29일 화요일 오전 11시(동부 표준시)에 '데이터 및 규제 촉매제 – 변화하는 환경 탐색'을 주제로 하는 대화형 토론에 참여할 예정입니다.
이 가상 행사는 투자자 및 관심 있는 분들이 실시간 웹캐스트로 참여할 수 있으며, 이후 회사 투자자 관계 웹사이트인 investors.elutia.com에서 녹화본도 제공될 예정입니다.
Elutia (Nasdaq : ELUT), leader dans les technologies de biomatrices à libération de médicaments, a annoncé sa participation à la série de conférences Chardan sur les enjeux actuels du développement pharmaceutique. La directrice scientifique de l’entreprise, le Dr Michelle LeRoux Williams, participera à une discussion informelle centrée sur « Données et catalyseurs réglementaires – Naviguer dans un paysage en évolution » le mardi 29 avril 2025 à 11h00 ET.
L’événement virtuel sera accessible aux investisseurs et aux parties intéressées via une diffusion en direct, avec une version enregistrée disponible ultérieurement sur le site des relations investisseurs de l’entreprise à investors.elutia.com.
Elutia (Nasdaq: ELUT), ein führendes Unternehmen im Bereich der medikamentenfreisetzenden Biomatrix-Technologien, hat seine Teilnahme an der Chardan Trending Issues in Drug Development Conference Series angekündigt. Die Chief Scientific Officer des Unternehmens, Dr. Michelle LeRoux Williams, wird an einem Gespräch am Kaminfeuer teilnehmen, das sich auf 'Daten- und regulatorische Katalysatoren – Navigation in einem sich wandelnden Umfeld' konzentriert, am Dienstag, den 29. April 2025, um 11:00 Uhr ET.
Die virtuelle Veranstaltung wird für Investoren und Interessierte über einen Live-Webcast zugänglich sein, mit einer später verfügbaren Aufzeichnung auf der Investor-Relations-Webseite des Unternehmens unter investors.elutia.com.
- None.
- None.
SILVER SPRING, Md., April 22, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix technologies, today announced that Michelle LeRoux Williams, Ph.D., Elutia’s Chief Scientific Officer, will participate in Chardan’s Trending Issues in Drug Development Conference Series on Tuesday, April 29, 2025.
Chardan's Data & Regulatory Catalysts – Navigating an Evolving Landscape – Virtual
Format: Fireside Chat
Date and Time: Tuesday, April 29, 2025, 11:00 a.m. ET (8:00 a.m. PT)
Webcast: Click Here
A live and archived webcast of the fireside chat will be available in the “Investors” section of the Elutia website at http://investors.elutia.com/.
About Elutia
Elutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable technologies, Elutia’s mission is humanizing medicine so patients can thrive without compromise. For more information, visit www.Elutia.com.
Investors:
Matt Steinberg
FINN Partners
matt.steinberg@finnpartners.com
This press release was published by a CLEAR® Verified individual.
FAQ
When is Elutia (ELUT) presenting at Chardan's Drug Development Conference 2025?
What is the topic of Elutia's (ELUT) presentation at the Chardan Conference?
How can investors watch Elutia's (ELUT) Chardan Conference presentation?
Who will represent Elutia (ELUT) at the Chardan Conference 2025?
